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RESEARCH NOTE INFECTIOUS DISEASESKPC-producing Klebsiella pneumoniae rectal
colonization is a risk factor for mortality in
patients with diabetic foot infectionsC. Tascini1, B. A. Lipsky2,3, E. Iacopi4, A. Ripoli5, F. Sbrana5,
A. Coppelli4, C. Goretti4, A. Piaggesi4 and F. Menichetti1
1) Infectious Diseases Unit, Cisanello Hospital, Pisa, Italy, 2) Division of
Medical Sciences (Infectious Diseases), University of Oxford, Oxford,
UK, 3) Department of Medicine (Infectious Diseases), University of Geneva,
Geneva, Switzerland, 4) Diabetic Foot Section, Department of Medicine,
University of Pisa and 5) Fondazione Toscana Gabriele Monasterio, Pisa, ItalyAbstractTo evaluate the relationship between carbapenemase-producing
Klebsiella pneumoniae (KPC-Kp) gut colonization and mortality in
diabetic patients with a foot infection (DFI) we performed a
single-centre, retrospective, matched case–control study. In the
study period, we identiﬁed 21 patients with DFI who had KPC-
Kp gut colonization and 21 controls. The 90-day mortality rate
was signiﬁcantly higher in patients with colonized guts (47%) than
the controls (4%) (p 0.013). A multivariate analysis demonstrated
that gut colonization with KPC-Kp was the only independent
predictor of mortality: odds ratio 13.33, 95% CI 1.90–272.80, p
0.024. In patients with DFI, KPC-Kp gut colonization appears to
be an important risk factor for mortality.
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p://dx.doi.org/10.1016/j.cmi.2015.04.010Infection caused by carbapenemase-producing Klebsiella pneu-
moniae (KPC-Kp) is a worldwide and growing problem causing
severe and difﬁcult-to-treat hospital epidemics [1] associated
with high-mortality rates [2–4]. In endemic or epidemic settings,
patients with diabetic foot infection (DFI) show a particularly
high risk of their gut becoming colonized with KPC-Kp for
several reasons: frequent need for acute-care hospitalization;
requirement for either re-vascularization procedures [5] or
lower-extremity amputation [6]; and prolonged, repeated
courses of antibiotic therapy (often with ﬂuoroquinolones) [7].
To evaluate the inﬂuence of KPC-Kp gut colonization on
overall mortality in DFI patients we performed a retrospective,
matched, case–control study in a tertiary-care University
Hospital in Pisa, Italy. During the study period (1 December
2010 to 31 March 2014) we identiﬁed patients cared for in our
diabetic foot clinic who had a rectal swab, as requested by the
attending physician for clinical or epidemiological reasons dur-
ing their hospital stay, that gave a positive result for KPC-Kp.
For each case patient with positive rectal swab we identiﬁed
a matched control patient with a DFI with similar characteris-
tics but no gut colonization. All the DFIs were managed with
microbiologically driven antibiotic therapy and surgery, if
needed [8]. Colonized patients were handled with standard
contact isolation procedures.
All diabetic foot wounds were classiﬁed according to the
University of Texas system [9]. We have described the
methods used for rectal swabs and other microbiological pro-
cedures elsewhere [10,11].
For the statistical analysis of the numerical data we calculated
the mean ± standard deviation or proportion and performed
comparisons between groups by two-sided unpaired Student’s t
test or chi-square test with continuity correction, as appro-
priate. We used logistic regression to identify independent
predictors of overall mortality. For covariates that showed a p
value <0.10 in the univariate regression we performed a
multivariate analysis, considering a p value <0.05 to be statis-
tically signiﬁcant. We conducted analyses with R statistical
software, version 2.11.1 (Bell Laboratories, New Providence,
NJ).
We identiﬁed 21 DFI patients with KPC-Kp gut colonization
and 21 controls. The two groups were well-matched for age
and sex. The University of Texas classiﬁcation of foot lesions
was similar: a 3D lesion was documented in 16 patients with gut
colonization (76%) and in 19 controls (90%) (p 0.408). The
Charlson comorbidity index was similar in the two groups:
8.19 ± 2.38 for the case group, 7.33 ± 2.20 in the control group,
(p 0.235). There was no difference in the number of previousious Diseases. Published by Elsevier Ltd. All rights reserved
TABLE 1. Comparison of clinical characteristics and outcomes
of patients with or without KPC-Kp gut colonization
Patients with
gut KPC-Kp
colonization
(n [ 21)
Patients without
gut KPC-Kp
colonization
(n [ 21) p
Age (years) 70 ± 11 70 ± 9 0.687
Male sex 9/21 (43%) 16/21 (76%) 0.059
University of Texas
3D classiﬁcationa
16/21 (76%) 19/21 (90%) 0.408
Charlson indexa 8.19 ± 2.38 7.33 ± 2.20 0.235
Previous admission(s) 1.81 ± 0.87 1.62 ± 0.92 0.495
KPC-Kp DFI 6/21 (29%) 0/21 (0%) 0.027
DFI not resolved 14/21 (66%) 11/21 (52%) 0.529
Overall mortality 10/21 (47%) 1/21 (5%) 0.005
Abbreviations: DFI, diabetic foot infection; KPC-Kp, carbapenemase-producing
Klebsiella pneumoniae.
aSee text for explanation.
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up (Table 1).
We documented six cases of DFI caused by KPC-Kp, all in
the case group (28.6%). Six patients in the case group (28.6%)
and four in the control group (19%) underwent major lower
extremity amputations (above the ankle). Antibiotic therapy
was always provided in case and control patients. In the case
group, antibiotic monotherapy was given in 67% of patients, but
it was given in 90% of patients in the control group. Infection
did not resolve in 14 case patients (67%) and in 11 of the
controls (52%) (p 0.529). The overall mortality at 3-month
follow up was signiﬁcantly higher in gut-colonized patients (10/
21, 47%) compared with patients in the control group (1/21,
5%) (p 0.005). Four of the six patients with infection caused by
KPC-Kp died (67%). By multivariate analysis, gut colonization
with KPC-Kp was the only independent predictor of mortal-
ity—odds ratio 13.33, 95% CI 1.90–272.80, p 0.024 (Table 2).
In this analysis, patients with gut colonization with KPC-Kp
had a signiﬁcantly higher mortality than matched controls.TABLE 2. Univariate and multivariate logistic regression
analyses for factors associate with mortality
Univariate regression Multivariate regression
Odds ratio
(95% CI) p
Odds ratio
(95% CI) p
Age (years) 1.05 (0.98–1.14) 0.188
Male sex 1.26 (0.3–5.67) 0.746
KPC-Kp gut colonization 18.17 (2.92–356.89) 0.009 13.33 (1.90–272.08) 0.024
KPC-Kp DFI 8.28 (1.35–69.38) 0.028 3.00 (0.44–27.13) 0.278
Charlson Indexa 0.92 (0.63–1.24) 0.604
University of Texas 3D
classiﬁcationa
0.87 (0.15–6.78) 0.875
Previous admission(s) 1.99 (0.89–5.06) 0.111
DFI, diabetic foot infection; KPC-Kp, carbapenemase-producing Klebsiella
pneumoniae.
aSee text for explanation.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InFurthermore, the subgroup of DFI patients with colonization
and infection due to KPC-Kp had a particularly high risk for
mortality. This risk was independent of the severity of the
diabetic foot wound, based on the University of Texas classi-
ﬁcation. It is noteworthy that the Charlson index was similar in
the two groups, suggesting that the presence of comorbidities
was not a signiﬁcant risk for mortality.
When caring for a DFI patient it would be useful to know if
the patient had KPC-Kp gut colonization, as antibiotics active
against this highly-resistant organism, e.g. colistin [7] and ami-
noglycosides, are associated with a relatively high risk of drug-
related adverse events; knowing a patient is not colonized could
limit the empiric use of these agents. Furthermore, the isolation
of patients either colonized or infected with antibiotic-resistant
pathogens may limit an outbreak, it may also be potentially
detrimental to the patient’s daily hospital care [12].
A key issue in this regard is whether the KPC-Kp coloniza-
tion affects the outcome of DFI patients per se, or merely
represents a marker of frailty or comorbidities of the patients
with a poor prognosis. Unfortunately, because of the small
sample size of our groups, we were unable to answer this
question, but it is noteworthy that six of the colonized patients
developed a KPC-Kp DFI and four of these died. In addition, it is
probable that some antibiotics (e.g. carbapenems, cephalospo-
rins) predispose more than others to KPC-Kp colonization, but
we had an insufﬁcient number of patients to address this issue
[13].
Other limitations of our study include its retrospective na-
ture and the lack of a systematic control of rectal swab in all
DFI patients. However, to our knowledge, this is the ﬁrst
report focusing on KPC gut colonization in DFI patients, a large
and growing patient population [14]. Our ﬁndings suggest that
in medical centres where KPC-Kp is endemic or epidemic,
clinicians should be aware of the potentially high risk of mor-
tality in colonized or infected patients and make efforts (e.g.
strict isolation procedures, antibiotic stewardship measures) to
avoid the acquisition and spread of this organism.Transparency declarationNone of the authors has any conﬂict of interest to disclose for
this work.AcknowledgementsWe received no ﬁnancial support from any source for this
study.fectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 790.e1–790.e3
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